Press Releases
2017
September 5, 2017
EnGeneIC Announces Publication in The Lancet Oncology of First Clinical Study Employing EDV™ Nanocell Platform to Enable microRNA Replacement Therapy
March 21, 2017
EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme
March 2, 2017
EnGeneIC Receives FDA Orphan Drug Designation for Targeted EDV™ Nanocells to Treat Glioblastoma Multiforme
2016
October 9, 2016
EnGeneIC Enters Into Research Collaboration with Takeda to Develop EDV™-Based Immunomodulatory Therapies for Oncology
April 7, 2016
EnGeneIC Announces Publication of Late-Stage Canine Brain Cancer Study Results in PLOS ONE
April 6, 2016
EnGeneIC Ltd. to Present at BIO CEO & Investor Conference 2016.
March 10, 2016
EnGeneIC receives Science Meets Business Top 25 Australian R&D spin-off companies award.
January 25, 2016
EnGeneIC Ltd. Strengthens Board of Directors to Support U.S. Expansion
January 5, 2016
EnGeneIC Limited to Present at the 34th Annual J.P. Morgan Healthcare Conference
2015
November 11, 2015
EnGeneIC Ltd. to Present at the Stifel 2015 Healthcare Conference
October 15, 2015
EnGeneIC Ltd. to Present at The 14th Annual BIO Investor Forum
September 16, 2015
EnGeneIC Ltd. to Initiate U.S. Phase 1 Clinical Study Using Targeted EDV™ Nanocells to Treat Advanced Glioma Patients
August 19, 2015
EnGeneIC Initiates Phase 1 Tailored-EDV Clinical Study in Solid Tumors
February 4, 2015
EnGeneIC to Present at BIO CEO & Investor Conference 2015
January 6, 2015
EnGeneIC Completes $10 Million Series B Financing Led by U.S. Institutional Investor
2014
November 10, 2014
EnGeneIC and Asbestos Diseases Research Institute Initiate MesomiR-1 Phase 1 Trial in Patients with Late Stage Mesothelioma
September 15, 2014
EnGeneIC Named a Recipient of the Cancer Institute NSW Premier’s Award for Excellence in Translational Cancer Research
August 11, 2014
EnGeneIC Receives Patent from the USPTO for EDV™ Nanocell Technology
June 24, 2014
EnGeneIC Unveils Clinical Development Strategy for EDV™ Nanocell Technology